Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotatercept - Merck & Co

Next Previous
Drug Profile

Sotatercept - Merck & Co

Alternative Names: ACE-011; ACTRIIA-Fc - Merck & Co; ActRIIA-IgG1Fc; Airwin; MK-7962; Sotatercept-csrk - Merck & Co; WINREVAIR

Latest Information Update: 22 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation; Indiana University; Merck & Co; University of Texas M. D. Anderson Cancer Center
  • Class Antianaemics; Antihypertensives; Antineoplastics; Immunoglobulin Fc fragments; Osteoporosis therapies; Recombinant fusion proteins
  • Mechanism of Action Activin inhibitors; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase II Pulmonary hypertension
  • Discontinued Anaemia; Beta-thalassaemia; Bone metastases; Chemotherapy-induced anaemia; Diamond-Blackfan syndrome; Myelodysplastic syndromes; Myelofibrosis; Postmenopausal osteoporosis; Renal osteodystrophy; Sickle cell anaemia; Vascular calcification

Most Recent Events

  • 15 Jun 2026 Merck plans a phase II trial for Pulmonary arterial hypertension (In infants, In children, In adolescents, Treatment experienced) in unknown location (SC, Injection) in August 2026 (NCT07646860)
  • 09 Apr 2026 Acceleron Pharma completes a phase II CADENCE trial for Pulmonary hypertension in USA, Spain, Germany, Belgium, Canada, France, Sweden, Italy, Israel, Mexico, Poland, and United Kingdom (SC) (NCT04945460)
  • 29 Mar 2026 Efficacy and adverse event data from a phase II CADENCE trial for Pulmonary arterial hypertension released by Merck

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top